Having said the above, it is not the time and level to sell off your stake. In fact it is a good level for those without a stake to buy some. It is a good risk versus reward situation, the management notwithstanding. It was reported that the first patient did express shRNA and in the next cohort there is a good chance to see efficacy as the dosage is very much increased.